Jenalyn Weekes

Jenalyn Weekes

Auto-generated profile, based on publicly available information

Jenalyn Weekes

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2025 in Science Advances
Verified
Journal Article
Open access
YZYe Zhang
Ye Zhang
LDLydie Debaize
Lydie Debaize
ALAdam Langenbucher
Adam Langenbucher
JWJenalyn Weekes
Jenalyn Weekes
IVIoulia Vogiatzi
Ioulia Vogiatzi
MMMark A. Murakami
Mark A. Murakami
Intratumor heterogeneity impacts disease progression and therapeutic resistance but remains poorly characterized by conventional histologic, immunophenotypic, and molecular approaches. Single-cell biophysical properties distinguish functional phenotypes complementary to these approaches, providing additional insight into cellular diversity. Here, we link both buoyant mass and stiffness to gene expression to identify clinically relevant phenotypes within primary mantle cell lymphoma (MCL) cells, using MCL as a model of biological and clinical diversity in human cancer. Linked measurements reveal that buoyant mass and stiffness characterize B cell development states from naïve to plasma cell and correlate with expression of oncogenic B cell receptor signaling genes such as BLK and CD79A . In addition, changes in cell buoyant mass within primary patient specimens ex vivo correlate with sensitivity to Bruton’s tyrosine kinase inhibitors in vivo in MCL and chronic lymphocytic leukemia, another B cell malignancy. These findings highlight the value of biophysical properties as biomarkers of response in pursuit of future precision therapeutic strategies.

27 May 2026 in Blood Advances
Verified
Journal Article
Open access
PDF file
RXRan Xu
Ran Xu
GWGongwei Wu
Gongwei Wu
SRSiobhan Rice
Siobhan Rice
MBMatthew Booker
Matthew Booker
JWJenalyn Celine Weekes
Jenalyn Celine Weekes
ALAndrew A Lane
Andrew A Lane
Many cancer therapies induce high response rates, with some resulting in undetectable disease as assessed using standard clinical assays. This is particularly true in leukemia and lymphoma, in which patients often achieve deep remission yet ultimately experience relapse. These outcomes highlight a critical need to better understand ultrarare persistent cells that survive therapy but remain inaccessible to current techniques. Here, we developed Live-cell Pick-Seq (LiP-Seq), an advanced platform leveraging multiplexed live-cell imaging to identify and retrieve individual target cells for downstream analysis. LiP-Seq enables high-resolution transcriptomic profiling of single, viable lymphoma cells present at frequencies as low as 10−6, providing a technological window into the biology of these elusive reservoirs. Applying this method to patients with mantle cell lymphoma after treatment with CD19 chimeric antigen receptor T-cell (CAR-T) therapy, we identified recurrent upregulation of the immune modulator IFITM2 in the persistent cell fraction. Functional validation demonstrated that IFITM2 overexpression conferred protection against CAR-T cytotoxicity in vitro, implicating it as a potential survival mechanism under therapeutic pressure. Our results provide, to our knowledge, the first transcriptomic characterization of viable, ultrarare persistent cells using LiP-Seq, establishing a new paradigm for identifying and targeting features that may enable treatment evasion.

11 July 2012 in European Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
LKLindsy Kass
Lindsy Kass
JWJ Weekes
J Weekes
LCLewis Carpenter
Lewis Carpenter

24 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
YZYe Zhang
Ye Zhang
LDLydie Debaize
Lydie Debaize
ALAdam Langenbucher
Adam Langenbucher
JWJenalyn Weekes
Jenalyn Weekes
IVIoulia Vogiatzi
Ioulia Vogiatzi
MMMark A. Murakami
Mark A. Murakami
Intra-tumor heterogeneity impacts disease progression and therapeutic resistance but remains poorly characterized by conventional histologic, immunophenotypic, and molecular approaches. Single-cell biophysical properties distinguish functional phenotypes complementary to these approaches, providing additional insight into cellular diversity. Here we link both buoyant mass and stiffness to gene expression to identify clinically relevant phenotypes within primary mantle cell lymphoma (MCL) cells, employing MCL as a model of biological and clinical diversity in human cancer. Linked measurements reveal that buoyant mass and stiffness characterize B-cell development states from naïve to plasma cell and correlate with expression of oncogenic B-cell receptor signaling genes such as BLK and CD79A . Additionally, changes in cell buoyant mass within primary patient specimens ex vivo correlate with sensitivity to Bruton’s Tyrosine Kinase inhibitors in vivo in MCL and chronic lymphocytic leukemia, another B-cell malignancy. These findings highlight the value of biophysical properties as biomarkers of response in pursuit of future precision therapeutic strategies.